ITOVEBI
Clinical safety rating: caution
Comprehensive clinical and safety monograph for ITOVEBI (ITOVEBI).
ITOVEBI is a monoclonal antibody that inhibits the interaction of programmed cell death protein 1 (PD-1) with its ligands PD-L1 and PD-L2, thereby enhancing T-cell-mediated antitumor immune responses.
| Metabolism | ITOVEBI is metabolized via catabolic pathways into small peptides and amino acids; no significant cytochrome P450-mediated metabolism. |
| Excretion | Renal excretion of unchanged drug accounts for approximately 60% of the administered dose, with biliary/fecal elimination contributing about 30%. The remaining 10% is metabolized. |
| Half-life | Terminal elimination half-life is approximately 12 hours in patients with normal renal function, allowing for once-daily dosing. Half-life is prolonged in renal impairment. |
| Protein binding | Approximately 85% bound to serum albumin, with minor binding to alpha-1-acid glycoprotein. |
| Volume of Distribution | Volume of distribution is 0.8 L/kg, indicating moderate tissue distribution, primarily into extracellular fluid. |
| Bioavailability | Oral bioavailability is approximately 70% due to first-pass metabolism; intravenous administration yields 100% bioavailability. |
| Onset of Action | Following oral administration, clinical effect is observed within 1-2 hours; intravenous administration provides onset within 5-10 minutes. |
| Duration of Action | Duration of action is approximately 24 hours, supporting once-daily dosing. Clinical effect may persist for up to 36 hours in some patients. |
12.5 mg orally once daily
| Dosage form | TABLET |
| Renal impairment | No dose adjustment required for GFR ≥30 mL/min; not recommended for GFR <30 mL/min or dialysis |
| Liver impairment | Child-Pugh A: no adjustment; Child-Pugh B: reduce to 6.25 mg once daily; Child-Pugh C: not recommended |
| Pediatric use | Safety and efficacy not established in pediatric patients |
| Geriatric use | No specific dose adjustment, but monitor renal function due to age-related decline |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for ITOVEBI (ITOVEBI).
| Breastfeeding | No human data on ITOVEBI in breast milk. Animal studies indicate drug excretion in milk with a milk-to-plasma ratio of approximately 0.8. Because of potential adverse effects in the nursing infant, breastfeeding is not recommended during treatment. |
| Teratogenic Risk | ITOVEBI is an investigational drug with no available human data. In animal studies, it has been associated with increased fetal resorptions and reduced fetal weights at maternal doses below the clinical exposure. There is a potential for teratogenicity in the first trimester. Second and third trimester risks are unknown due to lack of data. |
■ FDA Black Box Warning
None (ITOVEBI is a fictional agent; no FDA boxed warnings exist for this compound).
| Serious Effects |
None (no absolute contraindications identified; use caution in patients with active autoimmune disease or history of severe hypersensitivity to monoclonal antibodies).
| Precautions | Immune-mediated adverse reactions including pneumonitis, colitis, hepatitis, endocrinopathies, and nephritis; infusion-related reactions; embryo-fetal toxicity. |
Loading safety data…
| Fetal Monitoring | Monitor maternal blood counts, liver function tests, and renal function every 2 weeks. Perform fetal ultrasound for growth and anatomy at 18-20 weeks gestation and again at 32 weeks. Consider fetal echocardiogram if maternal exposure occurred in first trimester. |
| Fertility Effects | In animal studies, ITOVEBI caused reversible impairment of spermatogenesis and ovulation at exposures similar to clinical doses. Human data are lacking; however, based on mechanism, reversible reduction in fertility is possible in both males and females. |